The Cost of Psoriasis and Psoriatic Arthritis in 5 European Countries: A Systematic Review

Burgos-Pol, R.; Martínez-Sesmero, José Manuel; Ventura-Cerdá, J.M.; Elías, Isabel; Caloto, M.T.

doi:10.1016/j.adengl.2016.04.001

Cited by 45 publications

(46 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The substantial increase in psoriasis prevalence among CHS members in the presence of stable incidence is, therefore, compatible with increased overall longevity and longer disease duration. Rising psoriasis prevalence implies that the future economic burdens of psoriasis will continue to increase and may be of major importance to policymakers …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Incidence and prevalence of psoriasis in Israel between 2011 and 2017

Schonmann

Ashcroft

Iskandar

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background Psoriasis is a common chronic inflammatory skin disease associated with a heavy burden of morbidity, disability and cost. The occurrence of the disease in Israel has not been previously investigated. Objectives To provide standardized estimates of trends in psoriasis incidence, prevalence and mortality among patients in Israel between 2011 and 2017. Methods Using electronic health records from Clalit Health Services, the largest nationwide public health provider in Israel, we conducted a population‐based study investigating trends in the annual incidence and prevalence of psoriasis between the years 2011 and 2017. We report age‐ and sex‐adjusted rates, using the standard European population as a reference. Results We identified 71 094 incident psoriasis cases. The mean (SD) age of onset was 42.4 (21.0) years with a bimodal distribution, peaking in the early ‘30s and early ‘60s. Late‐onset psoriasis, occurring after 40 years of age, accounted for 51.1% of incident cases. The annual psoriasis incidence rate was constant throughout the study period (280/100 000 person‐years). Psoriasis prevalence rose from 2.5% in 2011 to 3.8% in 2017. Conclusions Psoriasis prevalence is increasing in Israel, although its incidence is stable. Clinicians and policymakers should plan to address the growing demands in the clinical, economic and societal burden of psoriasis.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Rising psoriasis prevalence implies that the future economic burdens of psoriasis will continue to increase and may be of major importance to policymakers. 37…”

Section: Interpretation Of the Findings And Comparison With Existing mentioning

confidence: 99%

Incidence and prevalence of psoriasis in Israel between 2011 and 2017

Schonmann

Ashcroft

Iskandar

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Psoriasis is a common disease that may have a considerable impact on the healthcare system . Therefore, appropriate use of therapeutic resources is very important.…”

Section: Introductionmentioning

confidence: 99%

Italian guidelines on the systemic treatments of moderate‐to‐severe plaque psoriasis

Gisondi

Altomare

Ayala

et al. 2017

Acad Dermatol Venereol

155

167

View full text Add to dashboard Cite

Psoriasis is a common disease, which has a considerable impact on the healthcare system. Therefore, appropriate use of therapeutic resources is very important. Management of psoriasis in daily clinical practice is highly variable because many issues are still debated and not definitely addressed by the evidence-based medicine. Moreover, the different availability and reimbursability of drugs in each country justifies national guidelines. Expert consensus can provide helpful guidelines for optimizing patient care. A total of 20 dermatologists from different areas of Italy and with large experience in the treatment of psoriasis agreed to participate in the guidelines expert panel who aimed to reach consensus on the factors influencing psoriasis severity, the indications for systemic treatments, the parameters to be considered in the choice of treatment, and the factors to be considered in the choice of biological treatment. The recommendations for the use, screening and monitoring of systemic therapies were based on the 2015 S3 European Dermatology Forum/European Academy of Dermatology and Venereology psoriasis guidelines. Recommendations on the treatment of psoriasis in special patient populations were also agreed. The final document was discussed in a meeting moderated by a facilitator with participation of the entire group and adopting a nominal group technique to reach consensus. A statement was regarded as consented when agreement was achieved by at least 75% of the voting experts according to the Delphi procedure.

show abstract

“…1 An estimated 1.3% to 2.6% of the population in the United Kingdom (UK) is affected by psoriasis. 3,4 Individuals of working age are generally affected by the disease, 5 and individuals with psoriasis are significantly more likely than those without to miss work for health-related reasons and to experience impaired productivity while at work. 3,4 Individuals of working age are generally affected by the disease, 5 and individuals with psoriasis are significantly more likely than those without to miss work for health-related reasons and to experience impaired productivity while at work.…”

Section: Introductionmentioning

confidence: 99%